Kornimate/medical-research-clean huggingface dataset:
the effects of gentle movements at the ankle in individuals with diminished range of motion

Conditions: Lateral Ankle Sprain

Summary: the purpose of this study is the examine the effects of gentle movements applied to the ankle joint and stretching on self-reported function, ankle motion and stiffness in individuals who have suffered from an ankle sprain within the last year and have decreased ankle motion.

the purpose of this study is the examine the effects of a grade iv anterior to posterior joint mobilization and stretching on self-reported function, dorsiflexion range of motion, talar glide and stiffness in individuals who have suffered from an ankle sprain within the last year and have a 5° dorsiflexion range of motion deficit. we will quantify range of motion with standard goniometric measures, stiffness with the use of an instrumented ankle arthrometer, talar glide with the use of the posterior talar glide test and self-reported function using the foot and ankle ability measure (faam) and faam-sport.

Eligibility criteria:
inclusion criteria: * history of a lateral ankle sprain within the last year * dorsiflexion range of motion deficit of 5° * return to full activity prior to participation in this study * individuals with dorsiflexion range of motion that is less than degrees of dorsiflexion. exclusion criteria: * a history of ankle surgery that involves intra-articular fixation * syndesmotic ankle sprain (to be ruled out based on the attending certified athletic trainers diagnosis) * a history or signs of reflex sympathetic dystrophy * suffer from an acute injury in the lower extremity within the last 6 weeks * have received manual therapy for the ankle sprain prior to enrollment

Keywords: ankle sprain joint mobilization manual therapy range of motion
comparison of nadifloxacin cream alone and with benzoyl peroxide solution in the treatment of acne

Conditions: Acne Vulgaris

Summary: the purpose of this study is to determine whether using of nadifloxacine 1% cream and benzoyl peroxide 5% solution together is more effective than using nadifloxacine alone in the treatment of mild to moderate facial acne.

nadifloxacin; a new topical antibiotic for the treatment of acne has recently been marketed in our country. only a few studies on its use and effectiviness could be found in the literature. nadifloxacin may be an alternative to other topical antibiotics and benzoyl peroxide or its use along with benzoyl peroxide may be more effective and rational to prevent possible future resistance.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of mild to moderate facial acne vulgaris * must have at least 10 inflammatory and/or non-inflammatory and no more than 3 nodulocystic acne lesions exclusion criteria: * nodulocystic acne lesions more than 3 and pure comedonal acne * additional truncal acne needs systemic therapy * usage of topical treatments for acne in last 2 weeks, systemic antibiotic in last 4 weeks, systemic isotretinoin in last 6 months * application of chemical peels and laser in last 4 weeks * usage of hormones in last 3 months * clinical signs of hyperandrogenism in females * pregrancy and lactation * hypersensitivity to interventions * additional facial skin diseases (eg. atopic and seborreic dermatitis) * photosensitive disorders and usage of drugs which can trigger photosensitive conditions

Keywords: acne nadifloxacin benzoyl peroxide
frontal eeg in ohca feasibility study

Conditions: Out-Of-Hospital Cardiac Arrest; BIS

Summary: this study aims to optimize the treatment of out-of-hospital cardiac arrest (ohca) by focusing on neurological outcomes through bispectral index (bis) monitoring. it will evaluate the feasibility of bis monitoring in the prehospital phase, assess the need for sedation based on bis values, and examine the timing of interventions in icu (intensive care unit) settings to identify irreversible hypoxic-ischemic brain injury (hibi).

the research project is designed to contribute to the low survival discharge rates of ohca patients in europe, which is currently around 8%. objectives: 1. to assess the feasibility of bis monitoring in the prehospital environment during cpr and rosc. 2. to determine the optimal mean bis cut-off value after rosc (return of spontaneous circulation) during the prehospital phase. 3. to assess bis and etco2 values in ohca patients under evaluation of cpr quality. 4. to understand the sedation needs based on bis values. 5. to identify the timing of interventions in the icu that signify irreversible hibi. phases: * phase 1: the initial focus is assessing bis and etco2 values in ohca patients receiving cpr. * phase 2: we will investigate whether patients with higher mean bis values (\>25) require earlier and more sedation than those with lower bis values. * phase 3: this phase will examine icu interventions and their timing to ascertain which patients are at risk of suffering from irreversible hibi. methodology: the project will utilize prehospital and icu settings for a multidisciplinary approach, integrating cardiological, neurological, and anesthesiological perspectives. a pilot phase of 5 patients will be conducted initially to fine-tune the protocol and address any technical issues with the equipment. timeline: the study will span approximately 14 months, starting with patient recruitment, data collection, and analysis and ending with the publication of results. this project aims to provide critical insights into the feasibility and effectiveness of bis monitoring in improving neurological outcomes for ohca patients.

Eligibility criteria:
inclusion criteria: * age ≥18 years * in out-of-hospital cardiac arrest (ohca) exclusion criteria: * bis application non-possible (for example, due to massive facial trauma) * no als (advanced life support) performed * clear signs of death * sustained rosc (\>5 minutes after cpr with signs of life) on the arrival of the emergency physician

Keywords: ohca bis rosc prehospital pru
recombinant human endostatin in combination with xelox therapy in patient with advanced colorectal cancer.

Conditions: Quality of Life

Summary: to study safety and efficacy of intravenous pump of recombinant human endostatin combined with xelox-treated and also investigate the potential value of cecs level for the prediction of pd and outcomes in patients with advanced colorectal cancer.


Eligibility criteria:
inclusion criteria: * clear pathology diagnosis of stage for the ⅳ period of advanced colorectal cancer. * there are at least 1 imaging examinations according to the standard of recist（the longest diameter is at least 10mm with spiral ct and 20mm with ordinary ct）. * male or female , age 18～75 * eastern cooperative oncology group (ecog) performance status of 0 or 1. * the patients had to have a life expectancy of at least 3 months. * a white blood count (wbc) greater than 3000/mm3, platelets greater than 100 000/mm3, and normal coagulation values. * aspartate aminotransferase (ast) and adenosine triphosphate (alt) values were to be less than 2.5 times the upper limit of normal;a bilirubin level of less than 25 lmol/l；a creatinine value less than 130 lmol/l. * informed consent was obtained from all patients. exclusion criteria: * patients having a brain tumor or brain metastases, a bleeding disorder, receiving anti-coagulant therapy. * a history of myocardial infarction or angina pectoris in the last 6 months or uncontrolled congestive heart failure, having an active infection or receiving radio- or chemotherapy within 4 weeks before study. * patients with uncontrolled serious medical or psychiatric illness or having any other condition that was likely to interfere with regular follow-up.
eribulin plus cisplatin versus gemcitabine plus cisplatin in triple negative breast cancer (tnbc)

Conditions: Breast Cancer

Summary: eribulin plus cisplatin versus gemcitabine plus cisplatin in triple negative breast cancer (tnbc)

a phase ii, single-center, randomized study of eribulin plus cisplatin (ep) versus gemcitabine plus cisplatin (gp) as first-line treatment in patients with advanced triple-negative breast cancer.

Eligibility criteria:
inclusion criteria: 1. females with age between 18 and 70 years old 2. histological proven unresectable recurrent or advanced breast cancer, including de novo stage iv disease. 3. triple-negative for estrogen receptor (er), progestogen receptor (pr), and human epithelial receptor-2 (her2) by immunohistochemistry (er \<1%, pr \<1% and her2 negative). a negative her2 gene amplification should be verified by fish test for those patients with her2 (2+). for those with her2 (1+), fish test might be considered by the investigator. 4. no prior chemotherapy for metastatic breast cancer is permitted. prior administration of chemotherapy in the adjuvant/neoadjuvant setting is acceptable if completed 6 months before the enrollment. 5. at least one measurable disease according to the response evaluation criteria in solid tumor (recist 1.1) 6. performance status no more than 1 7. all patients enrolled are required to have adequate hematologic, hepatic, and renal function 8. life expectancy longer than 12 weeks 9. no serious medical history of heart, lung, liver and kidney 10. be able to understand the study procedures and sign informed consent. 11. patients with good compliance. exclusion criteria: 1. pregnant or lactating women (female patients of child-bearing potential must have a negative serum pregnancy test within 14 days before the first day of drug dosing, or, if positive, a pregnancy should be ruled out by ultrasound) 2. women of child-bearing potential, unwilling to use adequate contraceptive protection during the process of the study 3. treatment with radiotherapy at the axial skeleton within 4 weeks before the first treatment or has not recovered from all toxicities of previous radiotherapy 4. treatment with an investigational product within 4 weeks before the first treatment 5. patients with symptomatic central nervous system metastases are not permitted, except for those with stable and asymptomatic brain metastases who have completed cranial irradiation, and have at least one measurable lesion outside the brain. radiotherapy should be completed within 4 weeks prior to the registration 6. other active malignancies (including other hematologic malignancies) or other malignancies within the last 5 years, except for cured nonmelanoma skin cancer or cervical intraepithelial neoplasia. 7. patients having a history of clinically significant cardiovascular, hepatic, respiratory or renal diseases, clinically significant hematological and endocrinal abnormalities, clinically significant neurological or psychiatric conditions 8. uncontrolled serious infection

Keywords: triple negative breast cancer first line chemotherapy eribulin cisplatin
postbiotic mbs and metformin combination in patients with t2dm

Conditions: Type-II Diabetes

Summary: the primary objective is to evaluate the effect of mbs treatment in human subjects, and to validate its impact on intestinal flora and diabetes symptoms on diabetic patients undertaking metformin. the scientific data collected will be referenced for future product development.


Eligibility criteria:
inclusion criteria: 1. male or female subject who aged from 20 to 70. 2. bmi in between 18.5 and 35 kg/m2 inclusively. 3. fasting blood sugar ≥ 126 mg/dl, and confirmed diagnosis of type-ii diabetes. 4. 30 days prior to the screening visit (v1), hba1c is steadily maintained in between 7-10% by medication. 5. prior to the screening visit (v1), subjects have been regularly taken 500-200 mg/day for at least 90 days. exclusion criteria: 1. pregnant or breastfeeding women or female subjects plan to enter pregnancy during study period. 2. subjects who are allergic to soy or products containing it. 3. at investigator's discretion, subjects are unlikely to comply with study procedures due to a history of alcohol or drug addiction. 4. subjects on vegetarian diet or other special diets (eg. ketogenic or gluten-free diets). 5. subjects have ongoing participation in another clinical trial that involves the use of investigational drugs, medical devices, dietary supplements, and/or cosmetics. 6. subject with impaired renal function confirmed by serum total bilirubin ≥ 1.5 upper limit of normal \[uln\], aspartate transaminase/ alanine transaminase (ast/alt) ≥ 2 uln, creatinine ≥ 2 uln or egfr \<60 ml/min/1.73 m\^2. 7. subjects who have been diagnosed with malignant tumors within five (5) years before the screening visit (v1) with exception to subjects with topical cancer but show significant recovery following investigator's assessment, such as basal or squamous cell skin cancer, superficial bladder cancer, or prostate or cervix or carcinoma in situ of the breast. 8. 30 days prior to screening visit (v1), subjects have taken antibiotics, synthetic drugs (sulfonamides, fluoroquinolone, etc.), anti-fungal or anti-viral medication but not limited to topical forms for use in skin application. 9. within 14 days prior to screening visit (v1), subjects have taken products or supplements that contain probiotics or prebiotics. 10. within 14 days prior to screening visit (v1), subjects experience diarrhea caused by gastrointestinal infection (3 times of watery stool within 24 hours). 11. within14 days prior to screening visit (v1), subjects have taken steroids, immunosuppressant, and/or inflammatory medicines. 12. subjects took or intend to take medications other than metformin that may affect intestinal flora within 30 days prior to screening visit, during screening period or whole trial period. examples of this kind of medication include dpp-4 inhibitors, glp-1 receptor agonists, acarbose, hypoglycemic sulfonamides, thiazolidinediones, sglt2 inhibitors, and insulin.

Keywords: diabetes mellitus (dm) diabetes t2dm mbs microbial
the effects of diet on small non-coding rna i sperm cells and the possible effects on reproductive success: diet intervention effects on sperm

Conditions: Changes in SncRNA in Sperm; Male Fertility; RNA Profile

Summary: in this study, patients with infertility treated with ivf at the center of reproductive medicine in linköping, sweden, will receive recipes and food according to nordic dietary guidelines. the purpose is to investigate whether a short diet intervention is sufficient to improve sperm quality and shift the small non-coding rna profile. in our previous study sperm showed rapid response to diet.

this study is a randomized controlled trial recruiting males seeking ivf treatment with their female partner at the center for reproductive medicine in linkoping, sweden. men will be randomized to a control group or diet intervention group. the intervention group will receive groceries with planned recipes during the hormonal treatment period for the woman (11-14 days) before ivf. the meal plan will be according to the nordic dietary guidelines and individualized to match total energy expenditure. the male partner must accept to participate in the diet intervention in order to be included and the female partner can choose to participate in the diet intervention but it is optional. sperm samples will be collected before the start of hormonal treatment and on ovum pick-up day. weight will be measured before and after the intervention. sperm samples will be processed as standard practice at the fertility clinic. sperm samples will be used for molecular analysis, such as small rna sequencing.

Eligibility criteria:
inclusion criteria: * male (biological) partner in infertile couple, scheduled for first ivf treatment * mature sperm cells in semen * able to speak and read swedish * omnivore * will refrain from nicotine and alcohol during intervention * sperm sampled provided no more than 3 weeks before intervention start exclusion criteria: * former or present malignant disease * former radiotherapy in pelvic area * former chemotherapy * known genetic/chromosomal disorder * food allergy

Keywords: male fertility small non-coding rna diet infertility reproduction diet intervention
analisys of neuromuscular response, postural balance and quality of life of diabetics type 2 after sensory-motor training: blind random controled clinical trial

Conditions: Diabetes Mellitus; Quality of Life; Exercise Therapy; Postural Balance

Summary: background: the individual's ability to sustain itself in the upright position, effectively adjusting the body's movements and reacting to external stimuli, postural control strategies represent essential activities of daily living. diabetes mellitus type 2 (dm-2) is considered a more problem of public health as having complications deficit in functional performance of the lower limbs and falls, which can interfere with the maintenance of balance, and is a strong predictor of functional limitations self referred. aim: to assess quality of life and the answers neuromuscular balance and baropodometric after sensory-motor training in patients with type 2 diabetes. method: to be recruited 50 volunteers aged between 45 to 64 years with dm-2, of both sexes, divided into two groups: 1) guidelines and 2) guidelines + sensory-motor training. biomechanical data will be collected (balance, baropodometry, electromyography strength and joint position sense), as well as questionnaires addqol and bestest. the intervention will be twice a week for 45 minutes for 12 weeks, divided into three phases: heating, sensory-motor training and cool-down, with monitoring of blood pressure and blood glucose. there will be a follow up after 3 months of intervention. statistical analysis will be used normality test to verify the data distribution and consistent statistical test for the appropriate comparisons within and between groups, and adopted a significance level of 5%. expected results: considering previous studies that demonstrate improvement in postural balance static and dynamic responses under the forward training protocol sensorimotor disease diabetes mellitus type 2, is expected to improve neuromuscular, balance, distribution plant, the joint position sense and the quality of life of voluntary dm-2. keywords: physical therapy modalities, exercise therapy, postural balance, diabetes mellitus, quality of life.


Eligibility criteria:
inclusion criteria: * diagnosis of diabetes mellitus type 2 with controlled blood glucose * absence of skin lesions or fractures of the lower limbs in the last 6 months -plantar malformations * severe postural abnormalities and limb length difference. exclusion criteria: * use of medications that can have negative effects on the function of cognition, attention and psychomotor (ie, opioids, antiepileptics, anxiolytics, antipsychotics, hypnotics and sedatives) * diagnosis of cardiovascular, neurological, rheumatological and musculoskeletal disorders that may interfere with activities of daily living * presence of vestibular disorders

Keywords: postural balance sensory motor trayning physical therapy modalities diabetes mellitus
fim-br - first-in-man study (brazil part) with sirolimus-coated bx velocity stent

Conditions: Coronary Artery Disease

Summary: this is a single center, non-randomized study. patients will be treated with the sirolimus coated bx velocity balloon-expandable stent mounted on the raptor otw sds. patients will have a repeat angiography at four months and will be followed for twelve months post-procedure.

this is a single center, non-randomized study of the bx velocity balloon-expandable stent coated with sirolimus (140µg/cm2) and formulated for fast or slow release. the sirolimus coated stent is mounted on the raptor otw sds. approximately 30 patients with de novo or restenotic native coronary artery lesions \ =3.0 to \>=3.5 mm in diameter by visual estimate who meet all eligibility criteria will be treated with the sirolimus coated bx velocity stent(s). patients will be followed for five years post-procedure and will have a repeat angiography at 4 months, 12 months, 24 months, and 48 months.

Eligibility criteria:
inclusion criteria: 1. diagnosis of angina pectoris as defined by canadian cardiovascular society classification (ccs) or a positive ischemia study; 2. single de novo or restenotic lesion requiring treatment in a major native coronary artery; 3. target lesion is \<=18mm in length (visual estimate); 4. target lesion is \>=3.0mm and \<=3.5mm in diameter (visual estimate); 5. target lesion stenosis is \>50% and \<100% (visual estimate); exclusion criteria: 1. a q-wave or non-q-wave myocardial infarction within the preceding 72 hours unless the ck and ck-mb enzymes are back to normal; 2. unprotected left main coronary disease with \>=50% stenosis; 3. have an ostial target lesion; 4. angiographic evidence of thrombus within target lesion; 5. calcified lesions which cannot be successfully predilated; 6. ejection fraction \<=30%; 7. target lesion involves bifurcation (either stenosis of both main vessel and major branch or stenosis of just major branch); 8. totally occluded vessel;
ceftriaxone to prevent pneumonia and inflammattion after cardiac arrest (protect)

Conditions: Out-Of-Hospital Cardiac Arrest; Pneumonia

Summary: randomized-controlled trial and microbiome assessment to understand the risk-to-benefit ratio of prophylactic antibiotics (ceftriaxone) vs placebo in patients with pneumonia and inflammation after cardiac arrest outside the hospital.

pneumonia is an infection of the lungs resulting in alveolar inflammation and fluid or purulent material accumulation. it is the most common infection after cardiac arrest occurring in up to 65% of patients treated with targeted temperature management. pneumonia may result from aspiration during cardiopulmonary resuscitation (cpr), or by introduction of oropharyngeal flora into the lungs during airway management. preventing infection after ohca may: 1) reduce exposure to broad-spectrum antibiotics and subsequent collateral damage, 2) prevent hemodynamic derangements due to local and systemic inflammation, and 3) prevent an association between infection and morbidity and mortality. these benefits must be balanced with the risk for altering bacterial resistomes in the absence clinical infection. accordingly, further study is warranted to understand the risk-to-benefit ratio of prophylactic antibiotics.

Eligibility criteria:
inclusion criteria: * ≥18 years of age * comatose (do not follow simple verbal commands) * have any initial heart rhythm (shockable or non-shockable) * ohca including the emergency department exclusion criteria: * name on opt-out list * in-hospital cardiac arrest * interval \>6 hours from icu admission to study drug receipt * preexisting terminal disease making 180-day survival unlikely * refused informed consent * emergent coronary artery bypass grafting * anaphylaxis or angioedema to beta-lactam antibiotics (i.e., cephalosporins or penicillins) * under legal guardianship or prisoner * known colonization with methicillin-resistant staphylococcus aureus (mrsa) or vancomycin-resistant enterococcus (vre) * clinical bacterial infection prior to hospital admission defined as any one of the following: * infectious prodrome preceding ohca * active course of antibiotics for infection prior to admission * active infection documented in the electronic medical record * family or surrogate endorsement of an active infection

Keywords: out-of-hospital cardiac arrest cardiac arrest pneumonia randomized clinical trial infection ceftriaxone microbiome inflammation prophylaxis